title: Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans.
abstract: Glucagon-like peptide-1 (GLP-1) relaxes the stomach during fasting but decreases hunger and food consumption and retards gastric emptying. The interrelationships between volume, emptying, and postprandial symptoms in response to GLP-1 are unclear. We performed, in healthy human volunteers, a placebo-controlled study of the effects of intravenous GLP-1 on gastric volume using (99m)Tc-single photon emission computed tomography imaging, gastric emptying of a nutrient liquid meal (Ensure) using scintigraphy, maximum tolerated volume (MTV) of Ensure, and postprandial symptoms 30 min after MTV. The role of vagal cholinergic function in the effects of GLP-1 was assessed by human pancreatic polypeptide (HPP) response to the Ensure meal. GLP-1 increased fasting and postprandial gastric volumes and retarded gastric emptying; MTV and postprandial symptoms were not different compared with controls. Effects on postprandial gastric function were associated with reduced postprandial HPP levels. GLP-1 does not induce postprandial symptoms despite significant inhibition of gastric emptying and vagal function; this may be partly explained by the increase in postprandial gastric volume.
authors.affiliation: Enteric Neuroscience Program, Gastroenterology Research Unit, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
authors.forename: Silvia
authors.initials: S
authors.lastname: Delgado-Aros
authors.forename: Doe-Young
authors.initials: DY
authors.lastname: Kim
authors.forename: Duane D
authors.initials: DD
authors.lastname: Burton
authors.forename: George M
authors.initials: GM
authors.lastname: Thomforde
authors.forename: Debra
authors.initials: D
authors.lastname: Stephens
authors.forename: Benjamin H
authors.initials: BH
authors.lastname: Brinkmann
authors.forename: Adrian
authors.initials: A
authors.lastname: Vella
authors.forename: Michael
authors.initials: M
authors.lastname: Camilleri
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D019422:Dietary Sucrose; D004311:Double-Blind Method; D005260:Female; D005502:Food; D005526:Food, Formulated; D005746:Gastric Emptying / Q000187:drug effects*; D005934:Glucagon / Q000008:administration & dosage / Q000494:pharmacology*; D052216:Glucagon-Like Peptide 1; D006801:Humans; D008297:Male; D010191:Pancreatic Polypeptide / Q000097:blood; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D010919:Placebos; D011498:Protein Precursors / Q000008:administration & dosage / Q000494:pharmacology*; D012527:Satiation / Q000502:physiology; D013270:Stomach / Q000033:anatomy & histology* / Q000187:drug effects*; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D001786:Blood Glucose; D019422:Dietary Sucrose; D010446:Peptide Fragments; D010919:Placebos; D011498:Protein Precursors; C082131:Ensure formulated food; D010191:Pancreatic Polypeptide; D052216:Glucagon-Like Peptide 1; D005934:Glucagon